Independent
Tenure on this board
5.5 yrs
Also a director at
Aldeyra Therapeutics Inc (ALDX)
3 nominees · 3 ballot items.
Three proposals: election of three Class III directors to serve three-year terms, ratification of PricewaterhouseCoopers LLP as the company’s independent registered public accounting firm for 2026, and an advisory (non-binding) vote to approve the compensation of the company’s named executive officers.
Elect three Class III directors (Nancy Miller-Rich, John F. Milligan, Ph.D., and Shawn Cline Tomasello, MBA) to hold office until the 2029 annual meeting.
Ratify the appointment of PricewaterhouseCoopers LLP as the Company’s independent registered public accounting firm for the fiscal year ending December 31, 2026.
An advisory, non-binding vote to approve the compensation of the Company’s named executive officers as disclosed in the proxy statement (the 'say-on-pay' vote).
This management proposal asks shareholders to cast a non-binding advisory vote to approve the company’s disclosed executive compensation for the named executive officers for 2025. Management is seeking endorsement to validate its pay design and implementation, which includes base salaries, annual performance-based cash bonuses (with corporate performance heavily weighted, particularly for the CEO), substantial 2025 equity awards (notably large option grants including a 480,000‑share inducement grant to the CFO), and change-in-control severance arrangements that provide enhanced payments and accelerated equity vesting in certain transactions. The proposal is statutory under Dodd-Frank and Rule 14a-21; it is explicitly non-binding but used by the Board and Compensation Committee to assess stockholder sentiment and guide future compensation decisions. The proxy discloses that the Compensation Committee engaged Radford for benchmarking and that pay outcomes in 2025 reflected above-target corporate performance adjustments, resulting in bonus payouts above target for certain NEOs. From a governance perspective, the advisory nature means investors will evaluate both the structure (performance-based weighting, risk-mitigation like clawback policy) and outcomes (size and timing of equity grants, severance protections), and the company notes it will consider shareholder feedback in future determinations. The pay-versus-performance disclosure in the proxy also shows significant equity-related accounting valuation movements and continuing net losses, which may concern some shareholders about alignment between realized executive pay and company financial performance. The Board’s recommendation to vote FOR is grounded in the belief that the compensation program supports retention, incentivizes performance, and aligns executives with long-term shareholder value, but investors should weigh the non-binding endorsement against specifics such as large option grants, change-in-control protections, and the company’s historical net losses when forming a voting decision. In sum, the vote is a governance signal: approval would endorse management’s approach and grant the Compensation Committee reassurance, whereas rejection would signal dissatisfaction and likely prompt further engagement and potential changes to compensation practices.
| # | Owner | % of shares | Shares | Value |
|---|---|---|---|---|
| 1 | JANUS HENDERSON GROUP PLC | 10.00% | 5,229,964 | $49M |
| 2 | RA CAPITAL MANAGEMENT, L.P. | 9.66% | 5,049,779 | $47M |
| 3 | GOLDMAN SACHS GROUP INC | 7.24% | 3,784,180 | $35M |
| 4 | Novo Holdings A/S | 6.98% | 3,650,737 | $34M |
| 5 | BVF INC/IL | 5.51% | 2,879,289 | $27M |
| 6 | STATE STREET CORP | 5.18% | 2,707,875 | $25M |
| 7 | VANGUARD CAPITAL MANAGEMENT LLC | 4.20% | 2,195,578 | $20M |
| 8 | ARMISTICE CAPITAL, LLC | 3.83% | 2,000,000 | $19M |
| 9 | BlackRock, Inc. | 3.67% | 1,920,955 | $18M |
| 10 | ADAGE CAPITAL PARTNERS GP, L.L.C. | 3.07% | 1,605,156 | $15M |
The opinions and information contained herein have been obtained or derived from sources believed to be reliable, but Boardroom Alpha cannot guarantee its accuracy and completeness, and that of the opinions based thereon.
This report contains opinions and is provided for informational purposes only – it does not constitute investment, legal or tax advice. You should not rely solely upon the research herein for purposes of transacting securities or other investments, and you are encouraged to conduct your own research and due diligence, and to seek the advice of a qualified securities professional before you make any investment.
None of the information contained in this report constitutes, or is intended to constitute a recommendation by Boardroom Alpha of any particular security or trading strategy or a determination by Boardroom Alpha that any security or trading strategy is suitable for any specific person. To the extent any of the information contained herein may be deemed to be investment advice, such information is impersonal and not tailored to the investment needs of any specific person.
No representation or warranty, expressed or implied, is made on behalf of Boardroom Alpha as to the accuracy or completeness of the information contained herein. Boardroom Alpha does not accept any liability for any direct, indirect or consequential loss or damage suffered by any person as a result of relying on all or any part of this research and any liability is expressly disclaimed.